BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wish JB, Aronoff GR, Bacon BR, Brugnara C, Eckardt KU, Ganz T, Macdougall IC, Núñez J, Perahia AJ, Wood JC. Positive Iron Balance in Chronic Kidney Disease: How Much is Too Much and How to Tell? Am J Nephrol 2018;47:72-83. [PMID: 29439253 DOI: 10.1159/000486968] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Ng WW, Shum H, To KK, Sridhar S. Emerging Infections Due to Shewanella spp.: A Case Series of 128 Cases Over 10 Years. Front Med 2022;9:850938. [DOI: 10.3389/fmed.2022.850938] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Wish JB, Anker SD, Butler J, Cases A, Stack AG, Macdougall IC. Iron Deficiency in CKD Without Concomitant Anemia. Kidney Int Rep 2021;6:2752-62. [PMID: 34805628 DOI: 10.1016/j.ekir.2021.07.032] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Bissinger R, Nemkov T, D'Alessandro A, Grau M, Dietz T, Bohnert BN, Essigke D, Wörn M, Schaefer L, Xiao M, Beirne JM, Kalo MZ, Schork A, Bakchoul T, Omage K, Kong L, Gonzalez-Menendez I, Quintanilla-Martinez L, Fehrenbacher B, Schaller M, Dhariwal A, Birkenfeld AL, Grahammer F, Qadri SM, Artunc F. Proteinuric chronic kidney disease is associated with altered red blood cell lifespan, deformability and metabolism. Kidney Int 2021:S0085-2538(21)00858-9. [PMID: 34537228 DOI: 10.1016/j.kint.2021.08.024] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
4 Borawski B, Malyszko JS, Kwiatkowska M, Malyszko J. Current Status of Renal Anemia Pharmacotherapy-What Can We Offer Today. J Clin Med 2021;10:4149. [PMID: 34575261 DOI: 10.3390/jcm10184149] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Mehta R, Cho ME, Cai X, Lee J, Chen J, He J, Flack J, Shafi T, Saraf SL, David V, Feldman HI, Isakova T, Wolf M; CRIC Study Investigators. Iron status, fibroblast growth factor 23 and cardiovascular and kidney outcomes in chronic kidney disease. Kidney Int 2021:S0085-2538(21)00731-6. [PMID: 34339746 DOI: 10.1016/j.kint.2021.07.013] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
6 Al-Mashdali A, Alyafei T, Yassin M. The Superiority of T2*MRI Over Serum Ferritin in the Evaluation of Secondary Iron Overload in a Chronic Kidney Disease Patient: A Case Report. J Blood Med 2021;12:665-70. [PMID: 34345192 DOI: 10.2147/JBM.S319591] [Reference Citation Analysis]
7 Guedes M, Muenz DG, Zee J, Bieber B, Stengel B, Massy ZA, Mansencal N, Wong MMY, Charytan DM, Reichel H, Waechter S, Pisoni RL, Robinson BM, Pecoits-Filho R; CKDopps Investigators. Serum Biomarkers of Iron Stores Are Associated with Increased Risk of All-Cause Mortality and Cardiovascular Events in Nondialysis CKD Patients, with or without Anemia. J Am Soc Nephrol 2021;32:2020-30. [PMID: 34244326 DOI: 10.1681/ASN.2020101531] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
8 Righini M, Dalmastri V, Capelli I, Orsi C, Donati G, Pallotti MG, Pedone C, Casella G, Chieco P, LA Manna G. Intravenous Iron Replacement Therapy Improves Cardiovascular Outcomes in Hemodialysis Patients. In Vivo 2021;35:1617-24. [PMID: 33910844 DOI: 10.21873/invivo.12419] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Cases A, Puchades MJ, de Sequera P, Quiroga B, Martin-Rodriguez L, Gorriz JL, Portolés J; en representación del Grupode Anemia de la S.E.N. Iron replacement therapy in the management of anaemia in non-dialysis Chronic kidney disease patients: Perspective of the Spanish Nephrology Society Anaemia Group. Nefrologia 2021;41:123-36. [PMID: 34053886 DOI: 10.1016/j.nefroe.2020.11.011] [Reference Citation Analysis]
10 Auerbach M, Staffa SJ, Brugnara C. Using Reticulocyte Hemoglobin Equivalent as a Marker for Iron Deficiency and Responsiveness to Iron Therapy. Mayo Clin Proc 2021;96:1510-9. [PMID: 33952394 DOI: 10.1016/j.mayocp.2020.10.042] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
11 Savković M, Simić-Ogrizović S, Dopsaj V. Assessment of positive iron balance in end-stage renal disease: Could hepcidin-25 be useful? Int J Lab Hematol 2021. [PMID: 33835732 DOI: 10.1111/ijlh.13539] [Reference Citation Analysis]
12 Richards T, Breymann C, Brookes MJ, Lindgren S, Macdougall IC, McMahon LP, Munro MG, Nemeth E, Rosano GMC, Schiefke I, Weiss G. Questions and answers on iron deficiency treatment selection and the use of intravenous iron in routine clinical practice. Ann Med 2021;53:274-85. [PMID: 33426933 DOI: 10.1080/07853890.2020.1867323] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
13 Dias GF, Grobe N, Rogg S, Jörg DJ, Pecoits-Filho R, Moreno-Amaral AN, Kotanko P. The Role of Eryptosis in the Pathogenesis of Renal Anemia: Insights From Basic Research and Mathematical Modeling. Front Cell Dev Biol 2020;8:598148. [PMID: 33363152 DOI: 10.3389/fcell.2020.598148] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
14 Del Vecchio L, Ekart R, Ferro CJ, Malyszko J, Mark PB, Ortiz A, Sarafidis P, Valdivielso JM, Mallamaci F; ERA-EDTA European Renal and Cardiovascular Medicine Working (EURECA-m) Group. Intravenous iron therapy and the cardiovascular system: risks and benefits. Clin Kidney J 2021;14:1067-76. [PMID: 34188903 DOI: 10.1093/ckj/sfaa212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
15 Kassianides X, Hazara AM, Bhandari S. Improving the safety of intravenous iron treatments for patients with chronic kidney disease. Expert Opin Drug Saf 2021;20:23-35. [PMID: 33203251 DOI: 10.1080/14740338.2021.1853098] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
16 Tomasz G, Ewa W, Jolanta M. Biomarkers of iron metabolism in chronic kidney disease. Int Urol Nephrol 2021;53:935-44. [PMID: 33025407 DOI: 10.1007/s11255-020-02663-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
17 Thévenod F, Lee WK, Garrick MD. Iron and Cadmium Entry Into Renal Mitochondria: Physiological and Toxicological Implications. Front Cell Dev Biol 2020;8:848. [PMID: 32984336 DOI: 10.3389/fcell.2020.00848] [Cited by in Crossref: 4] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
18 Alageeli AA, Alqahtany FS, Algahtani FH. The Role of Reticulocyte Hemoglobin Content for the Diagnosis of Functional Iron Deficiency in Hemodialyzed patients. Saudi J Biol Sci 2021;28:50-4. [PMID: 33424282 DOI: 10.1016/j.sjbs.2020.08.030] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
19 Ambarsari CG, Trihono PP, Kadaristiana A, Rachmadi D, Andriastuti M, Puspitasari HA, Tambunan T, Pardede SO, Mangunatmadja I, Hidayati EL. Low-Dose Maintenance Intravenous Iron Therapy Can Prevent Anemia in Children with End-Stage Renal Disease Undergoing Chronic Hemodialysis. Int J Nephrol 2020;2020:3067453. [PMID: 32566294 DOI: 10.1155/2020/3067453] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Macdougall IC, Comin-Colet J, Breymann C, Spahn DR, Koutroubakis IE. Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency. Adv Ther 2020;37:1960-2002. [PMID: 32297281 DOI: 10.1007/s12325-020-01323-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
21 Ganz T, Aronoff GR, Gaillard CAJM, Goodnough LT, Macdougall IC, Mayer G, Porto G, Winkelmayer WC, Wish JB. Iron Administration, Infection, and Anemia Management in CKD: Untangling the Effects of Intravenous Iron Therapy on Immunity and Infection Risk. Kidney Med 2020;2:341-53. [PMID: 32734254 DOI: 10.1016/j.xkme.2020.01.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
22 Wilk A, Szypulska-Koziarska D, Marchelek-Myśliwiec M, Głazek W, Wiszniewska B. Serum Selenium, Iron, Zinc, and Copper Concentrations in Renal Transplant Recipients Treated with Mycophenolate Mofetil. Biol Trace Elem Res 2020;198:371-9. [PMID: 32072447 DOI: 10.1007/s12011-020-02074-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
23 Rostoker G, Laroudie M, Blanc R, Griuncelli M, Loridon C, Lepeytre F, Rabaté C, Cohen Y. Histological Scores Validate the Accuracy of Hepatic Iron Load Measured by Signal Intensity Ratio and R2* Relaxometry MRI in Dialysis Patients. J Clin Med 2019;9:E17. [PMID: 31861625 DOI: 10.3390/jcm9010017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
24 Fandrey J, Schödel J, Eckardt KU, Katschinski DM, Wenger RH. Now a Nobel gas: oxygen. Pflugers Arch 2019;471:1343-58. [PMID: 31754831 DOI: 10.1007/s00424-019-02334-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
25 Rognoni C, Ortalda V, Biasi C, Gambaro G. Economic Evaluation of Ferric Carboxymaltose for the Management of Hemodialysis Patients with Iron Deficiency Anemia in Italy. Adv Ther 2019;36:3253-64. [PMID: 31489572 DOI: 10.1007/s12325-019-01089-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
26 Begum S, Latunde-Dada GO. Anemia of Inflammation with An Emphasis on Chronic Kidney Disease. Nutrients 2019;11:E2424. [PMID: 31614529 DOI: 10.3390/nu11102424] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
27 Macdougall IC. Intravenous Iron Use in the Care of Patients with Kidney Disease. Clin J Am Soc Nephrol 2019;14:1528-30. [PMID: 31175103 DOI: 10.2215/CJN.00510119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 van Swelm RPL, Wetzels JFM, Swinkels DW. The multifaceted role of iron in renal health and disease. Nat Rev Nephrol 2020;16:77-98. [PMID: 31554933 DOI: 10.1038/s41581-019-0197-5] [Cited by in Crossref: 43] [Cited by in F6Publishing: 81] [Article Influence: 14.3] [Reference Citation Analysis]
29 Rostoker G, Vaziri ND. Risk of iron overload with chronic indiscriminate use of intravenous iron products in ESRD and IBD populations. Heliyon 2019;5:e02045. [PMID: 31338466 DOI: 10.1016/j.heliyon.2019.e02045] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
30 Kshirsagar AV, Li X. Long-Term Risks of Intravenous Iron in End-Stage Renal Disease Patients. Adv Chronic Kidney Dis 2019;26:292-7. [PMID: 31477259 DOI: 10.1053/j.ackd.2019.05.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
31 Malyszko J, Malyszko JS, Matuszkiewicz-Rowinska J. Hepcidin as a therapeutic target for anemia and inflammation associated with chronic kidney disease. Expert Opin Ther Targets 2019;23:407-21. [PMID: 30907175 DOI: 10.1080/14728222.2019.1599358] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
32 Spinowitz B, Pecoits-Filho R, Winkelmayer WC, Pergola PE, Rochette S, Thompson-Leduc P, Lefebvre P, Shafai G, Bozas A, Sanon M, Krasa HB. Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review. J Med Econ 2019;22:593-604. [PMID: 30813807 DOI: 10.1080/13696998.2019.1588738] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
33 Sun L, Zou L, Lu Y, Deng N, Wang H. Effect of Serum Hepcidin on Predicting Mortality in Hemodialysis Patients: A Prospective Cohort Study. Iran Red Crescent Med J 2019;In Press. [DOI: 10.5812/ircmj.87091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
34 Yeh SC, Lin YC, Hong YC, Hsu CC, Lin YC, Wu MS. Different Effects of Iron Indices on Mortality in Patients With Autosomal Dominant Polycystic Kidney Disease After Long-Term Hemodialysis: A Nationwide Population-Based Study. J Ren Nutr 2019;29:444-53. [PMID: 30683605 DOI: 10.1053/j.jrn.2018.11.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
35 Camaschella C. Iron deficiency. Blood 2019;133:30-9. [DOI: 10.1182/blood-2018-05-815944] [Cited by in Crossref: 121] [Cited by in F6Publishing: 159] [Article Influence: 40.3] [Reference Citation Analysis]
36 Drüeke TB. Lessons from clinical trials with erythropoiesis-stimulating agents (ESAs). Ren Replace Ther 2018;4. [DOI: 10.1186/s41100-018-0187-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
37 Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood. 2019;133:40-50. [PMID: 30401705 DOI: 10.1182/blood-2018-06-856500] [Cited by in Crossref: 192] [Cited by in F6Publishing: 268] [Article Influence: 48.0] [Reference Citation Analysis]
38 Vera-Aviles M, Vantana E, Kardinasari E, Koh NL, Latunde-Dada GO. Protective Role of Histidine Supplementation Against Oxidative Stress Damage in the Management of Anemia of Chronic Kidney Disease. Pharmaceuticals (Basel) 2018;11:E111. [PMID: 30347874 DOI: 10.3390/ph11040111] [Cited by in Crossref: 18] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
39 Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, McMurray JJV, Murray H, Steenkamp R, Tomson CRV, Wheeler DC, Winearls CG, Ford I; on behalf of the PIVOTAL Trial investigators. Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data. Am J Nephrol 2018;48:260-8. [PMID: 30304714 DOI: 10.1159/000493551] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
40 Rostoker G. When should iron supplementation in dialysis patients be avoided, minimized or withdrawn? Semin Dial 2019;32:22-9. [PMID: 29956370 DOI: 10.1111/sdi.12732] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
41 Macdougall IC. Iron therapy for managing anaemia in chronic kidney disease. Curr Opin Nephrol Hypertens 2018;27:358-63. [PMID: 29905580 DOI: 10.1097/MNH.0000000000000436] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]